1. Home
  2. CBNK vs ADCT Comparison

CBNK vs ADCT Comparison

Compare CBNK & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CBNK

Capital Bancorp Inc.

HOLD

Current Price

$33.70

Market Cap

519.9M

Sector

Finance

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$1.09

Market Cap

431.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBNK
ADCT
Founded
1974
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
519.9M
431.2M
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
CBNK
ADCT
Price
$33.70
$1.09
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
$35.50
$7.75
AVG Volume (30 Days)
55.4K
2.7M
Earning Date
04-27-2026
05-04-2026
Dividend Yield
1.52%
N/A
EPS Growth
60.85
30.86
EPS
0.73
N/A
Revenue
N/A
$81,357,000.00
Revenue This Year
$16.20
N/A
Revenue Next Year
$8.52
$66.49
P/E Ratio
$45.90
N/A
Revenue Growth
N/A
14.85
52 Week Low
$26.40
$0.78
52 Week High
$36.40
$4.98

Technical Indicators

Market Signals
Indicator
CBNK
ADCT
Relative Strength Index (RSI) 68.12 15.96
Support Level $30.00 N/A
Resistance Level $35.00 $4.77
Average True Range (ATR) 0.87 0.18
MACD 0.21 -0.22
Stochastic Oscillator 92.69 10.44

Price Performance

Historical Comparison
CBNK
ADCT

About CBNK Capital Bancorp Inc.

Capital Bancorp Inc is a bank holding company. The company through its holdings operates as a commercial-focused community bank that serves businesses, not-for-profit associations, and entrepreneurs throughout the region. The bank operates through four divisions including Commercial Banking, Capital Bank Home Loans, OpenSky, and Windsor Advantage. The company generates majority revenue from the Commercial bank sector. Commercial Banking division focuses on providing personalized service to commercial clients throughout the operations supplemented by lending outside primary market as well as engaging in government guaranteed lending on a national basis.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: